Topical treatment of venereal warts: a comparative open study of podophyllotoxin cream versus solution.
Podophyllotoxin solution (0.5%) is licensed for use in the treatment of condylomata acuminata (genital warts) in men in a number of European countries. In some countries, approval also extends to treatment of genital warts in women. This controlled randomized prospective study evaluated the efficacy and safety of a cream formulation of podophyllotoxin at 2 concentrations (0.15% and 0.3%), using 0.5% podophyllotoxin solution as a reference treatment. Two separate studies were initiated, to assess the 3 treatment groups in (a) male patients, and (b) female patients. Statistical evaluation was based on a "response rate' calculated at each clinic visit. The mean "response rates' in the male patient study at 4 weeks were 75.1%, 79.0% and 85.6% in the 0.15% cream, 0.3% cream and 0.5% solution groups, respectively. The corresponding "response rates' for the female patient study were 86.2%, 92.6%, and 93.1%, respectively. The relapse rates for both male and female patients were 6.0% in the 0.15% cream group, 8.6% in the 0.3% cream group and 8.6% in the 0.5% solution group. The results show that there were no statistically significant differences between the 3 treatments with regard to both efficacy and safety. This was true for both the male and female patient groups.
Claesson
U
U
Vasastadens Läkarmottgn., Skövde, Sweden.
Lassus
A
A
Happonen
H
H
Hogström
L
L
Siboulet
A
A
D000287:Administration, Topical; D000328:Adult; D003218:Condylomata Acuminata / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage*; D008297:Male; D009824:Ointments; D010409:Penile Diseases / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000008:administration & dosage*; D012008:Recurrence; D012996:Solutions; D014845:Vulvar Diseases / Q000188:drug therapy*
D007641:Keratolytic Agents; D009824:Ointments; D012996:Solutions; D011034:Podophyllotoxin